SAN FRANCISCO, June 25, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs […]
Other News
Samuel E. Navarro Appointed to BioSig Board of Directors
Santa Monica, CA, June 25, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform designed to address an unmet need for the electrophysiology (EP) marketplace, today appointed Samuel E. Navarro to its Board of Directors. Mr. Navarro brings to BioSig […]
InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure
SOUTH SAN FRANCISCO–(BUSINESS WIRE)–InterVene Inc. today announced it has raised $15 million in a Series B financing round. The company’s BlueLeaf® Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) — the failure of venous valves in the legs — that does not require an implant. […]
MemorialCare Saddleback Medical Center Cardiologists Successfully Implant Device to Reduce Stroke Risk
LAGUNA HILLS, Calif., June 24, 2019 /PRNewswire/ — MemorialCare Saddleback Medical Center cardiologists are among a select group of specialists to successfully implant a device in patients to help keep harmful blood clots from entering the blood stream and potentially causing a stroke. Cardiologists Cheng-Han Chen, M.D., Ph.D.; John Bahadorani, M.D.; Paul Drury, M.D., and Ashish Shah, […]
Acutus Medical Announces $170 Million Financing
CARLSBAD, California, June 24, 2019 /PRNewswire/ — Acutus Medical today announced a $170 million financing, including a $100 million Series D equity financing and a $70 million credit facility. The funding is intended to accelerate commercialization and facilitate global business development activities as the company continues to transform arrhythmia care through distinct, innovative technologies designed to provide physicians and patients […]
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This research is part of MyoKardia’s efforts aimed at […]
CMS Decision on TAVR Puts Patients at the End of the Line, says Heart Valve Voice
WASHINGTON, June 24, 2019 /PRNewswire/ — The Centers for Medicaid and Medicare Services last Friday issued their final National Coverage Decision on how hospitals will be approved to do the TAVR (transaortic valve replacement) procedure, a less invasive valve replacement treatment that avoids open heart surgery and allows patients to resume daily life […]
Micro Medical Solutions Receives FDA IDE Approval for Pivotal Clinical Trial of MicroStent
WILMINGTON, Mass., June 24, 2019 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced today that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). IDE approval allows MMS to initiate […]
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
VANCOUVER, June 24, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion […]
Avinger to Effect One-for-Ten Reverse Stock Split
REDWOOD CITY, Calif., June 21, 2019 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-10 reverse stock split of the Company’s common stock, which […]



